|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
50,230,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Icosavax is a biopharmaceutical company utilizing its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Co.'s pipeline includes vaccine candidates targeting some of viral causes of pneumonia. Co.'s vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus, and IVX-241, a vaccine candidate designed to target human metapneumovirus. Co. is developing additional vaccine candidates to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
225,965 |
272,386 |
481,304 |
| Total Sell Value |
$0 |
$3,496,502 |
$3,919,051 |
$6,446,684 |
| Total People Sold |
0 |
4 |
5 |
7 |
| Total Sell Transactions |
0 |
8 |
14 |
44 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nicholson Jonathan |
Former 10% Owner |
– – – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,749,995 |
2,749,995 |
|
- |
|
| Adams Street Partners Llc |
Former 10% Owner |
– – – |
2021-08-02 |
4 |
B |
$15.00 |
$2,000,010 |
I/I |
133,334 |
256,783 |
0.01 |
- |
|
| Adams Street Partners Llc |
Former 10% Owner |
– – – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,259,058 |
244,415 |
|
- |
|
| Gould Terry P |
Director |
– • – |
2021-08-02 |
4 |
B |
$15.00 |
$2,000,010 |
I/I |
133,334 |
256,783 |
2.1 |
- |
|
| Gould Terry P |
Director |
– • – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,259,058 |
244,415 |
|
- |
|
| Sanofi-Aventis |
10% Owner |
– – • |
2021-08-02 |
4 |
B |
$15.00 |
$1,000,005 |
I/I |
66,667 |
3,155,169 |
1.5 |
- |
|
| Sanofi-Aventis |
10% Owner |
– – • |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,088,502 |
3,088,502 |
|
- |
|
| Mcdade Mark |
Former 10% Owner |
– – – |
2021-08-02 |
4 |
B |
$15.00 |
$3,320,265 |
D/D |
221,351 |
3,523,561 |
2.44 |
- |
|
| Mcdade Mark |
Former 10% Owner |
– – – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,310,228 |
3,310,228 |
|
- |
|
| Kanesa-Thasan Niranjan |
Chief Medical Officer |
• – – |
2021-08-02 |
4 |
B |
$15.00 |
$99,990 |
D/D |
6,666 |
6,666 |
2.74 |
- |
|
| Holtzman Douglas |
Chief Scientific Officer |
• – – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
I/I |
52,440 |
52,440 |
|
- |
|
| Russo Thomas Joseph |
Chief Financial Officer |
• – – |
2021-07-30 |
4 |
A |
$15.00 |
$487,500 |
D/D |
32,500 |
32,500 |
|
- |
|
| Cearley Cassia |
Chief Business Officer |
• – – |
2021-07-30 |
4 |
A |
$15.00 |
$416,250 |
D/D |
27,750 |
62,893 |
|
- |
|
| Simpson Adam K. |
Chief Executive Officer |
• • – |
2021-07-30 |
4 |
A |
$15.00 |
$1,875,000 |
D/D |
125,000 |
125,000 |
|
- |
|
| Veneman Ann M |
Director |
– • – |
2021-07-30 |
4 |
A |
$15.00 |
$127,500 |
D/D |
8,500 |
8,500 |
|
- |
|
| Kunz Heidi |
Director |
– • – |
2021-07-30 |
4 |
A |
$15.00 |
$131,250 |
D/D |
8,750 |
8,750 |
|
- |
|
| Kanesa-Thasan Niranjan |
Chief Medical Officer |
• – – |
2021-07-30 |
4 |
A |
$15.00 |
$622,500 |
D/D |
41,500 |
168,656 |
|
- |
|
| Richardson Charles E |
See Remarks |
• – – |
2021-07-30 |
4 |
A |
$15.00 |
$416,250 |
D/D |
27,750 |
78,883 |
|
- |
|
| Holtzman Douglas |
Chief Scientific Officer |
• – – |
2021-07-30 |
4 |
A |
$15.00 |
$622,500 |
D/D |
41,500 |
282,482 |
|
- |
|
119 Records found
|
|
Page 5 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
